These decades-old medicines
command very low prices in the U.S.
and the FDA admits that
some companies opt to
stop producing the
medications, that are among
the most effective for
breast cancer
lung cancer
head and neck cancer [ NY TIMES
Christina Jewett interviewed Dr.
Andrew Shuman, U of Michigan
prof. and med school professor ]
No comments:
Post a Comment